ArticleBMJ oncology2026

SAFFRON-301: a randomised phase III study of sitravatinib in combination with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer.

Qing Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.